Seelos Therapeutics Inc. (NASDAQ:SEEL) has a beta value of 2.99 and has seen 2,752,699 shares traded in the last trading session. The company, currently valued at $476.74 Million, closed the last trade at $6.09 per share which meant it lost -$0.13 on the day or -2.09% during that session. The SEEL stock price is -3.45% off its 52-week high price of $6.3 and 92.78% above the 52-week low of $0.44. If we look at the company’s 10-day average daily trading volume, we find that it stood at 10.24 Million shares traded. The 3-month trading volume is 9.89 Million shares.
The consensus among analysts is that Seelos Therapeutics Inc. (SEEL) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 4 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.09.
Seelos Therapeutics Inc. (NASDAQ:SEEL) trade information
Despite being -2.09% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Apr 27 when the SEEL stock price touched $6.60-7 or saw a rise of 7.73%. Year-to-date, Seelos Therapeutics Inc. shares have moved 285.44%, while the 5-day performance has seen it change -2.56%. Over the past 30 days, the shares of Seelos Therapeutics Inc. (NASDAQ:SEEL) have changed 22.78%. Short interest in the company has seen 5.35 Million shares shorted with days to cover at 0.54.
Wall Street analysts have a consensus price target for the stock at $11.75, which means that the shares’ value could jump 92.94% from current levels. The projected low price target is $6 while the price target rests at a high of $15. In that case, then, we find that the current price level is +146.31% off the targeted high while a plunge would see the stock lose -1.48% from current levels.
Seelos Therapeutics Inc. (SEEL) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +67.3% over the past 5 years. Earnings growth for 2021 is a modest +83.1%.
Seelos Therapeutics Inc. (NASDAQ:SEEL)’s Major holders
Insiders own 6.57% of the company shares, while shares held by institutions stand at 12.78% with a share float percentage of 13.68%. Investors are also buoyed by the number of investors in a company, with Seelos Therapeutics Inc. having a total of 47 institutions that hold shares in the company. The top two institutional holders are Vanguard Group Inc. (The) with over 2.8 Million shares worth more than $4.42 Million. As of December 30, 2020, Vanguard Group Inc. (The) held 3.58% of shares outstanding.
The other major institutional holder is Uniplan Investment Counsel Inc., with the holding of over 1.93 Million shares as of December 30, 2020. The firm’s total holdings are worth over $3.04 Million and represent 2.46% of shares outstanding.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Also the top two Mutual Funds that are holding company’s shares are Invesco ETF Tr-Invesco DWA Healthcare Momentum ETF and Vanguard Total Stock Market Index Fund. As of March 30, 2021, the former fund manager holds about 4.43% shares in the company for having 3464259 shares of worth $17.29 Million while later fund manager owns 2.32 Million shares of worth $3.66 Million as of December 30, 2020, which makes it owner of about 2.96% of company’s outstanding stock.